Jason Cai, PhD

• Bernadette Marquez-Nostra
• David Matuskey
• Irina Esterlis
• Nabeel Nabulsi
• Richard Carson
• Stephen Strittmatter
• Yiyun Huang

Alzheimer Disease; Chemistry, Pharmaceutical; Pharmacokinetics; Pharmacology; Biomarkers; Neurodegenerative Diseases; Positron-Emission Tomography; Drug Discovery; Drug Development

Aging; Biomarkers

• Neuronal transcriptome, tau and synapse loss in Alzheimer’s knock-in mice require prion proteinStoner A, Fu L, Nicholson L, Zheng C, Toyonaga T, Spurrier J, Laird W, Cai Z, Strittmatter S. Neuronal transcriptome, tau and synapse loss in Alzheimer’s knock-in mice require prion protein. Alzheimer's Research & Therapy 2023, 15: 201. PMID: 37968719, PMCID: PMC10647125, DOI: 10.1186/s13195-023-01345-z.
• Decreased Synaptic Vesicle Glycoprotein 2A Binding in the Human Postmortem Essential Tremor Cerebellum: Evidence of Reduction in Synaptic DensityYang Y, Zheng C, Chen B, Hernandez N, Faust P, Cai Z, Louis E, Matuskey D. Decreased Synaptic Vesicle Glycoprotein 2A Binding in the Human Postmortem Essential Tremor Cerebellum: Evidence of Reduction in Synaptic Density. The Cerebellum 2023, 1-8. PMID: 37783917, DOI: 10.1007/s12311-023-01611-8.
• Preclinical evaluation of a brain penetrant PARP PET imaging probe in rat glioblastoma and nonhuman primatesChen B, Ojha D, Toyonaga T, Tong J, Pracitto R, Thomas M, Liu M, Kapinos M, Zhang L, Zheng M, Holden D, Fowles K, Ropchan J, Nabulsi N, De Feyter H, Carson R, Huang Y, Cai Z. Preclinical evaluation of a brain penetrant PARP PET imaging probe in rat glioblastoma and nonhuman primates. European Journal Of Nuclear Medicine And Molecular Imaging 2023, 50: 2081-2099. PMID: 36849748, DOI: 10.1007/s00259-023-06162-y.
• Decreased synaptic vesicle glycoprotein 2A binding in a rodent model of familial Alzheimer's disease detected by [18F]SDM-16Zheng C, Toyonaga T, Chen B, Nicholson L, Mennie W, Liu M, Spurrier J, Deluca K, Strittmatter S, Carson R, Huang Y, Cai Z. Decreased synaptic vesicle glycoprotein 2A binding in a rodent model of familial Alzheimer's disease detected by [18F]SDM-16. Frontiers In Neurology 2023, 14: 1045644. PMID: 36846134, PMCID: PMC9945093, DOI: 10.3389/fneur.2023.1045644.
• Visualization of synaptic vesicle protein 2A in a rodent model of familial Alzheimer’s disease with a metabolically stable PET probeZheng C, Chen B, Toyonaga T, Liu M, Nicholson L, Deluca K, Strittmatter S, Carson R, Huang Y, Cai Z. Visualization of synaptic vesicle protein 2A in a rodent model of familial Alzheimer’s disease with a metabolically stable PET probe. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.063890.
• Poly (ADP-ribose) polymerases as PET imaging targets for central nervous system diseasesTong J, Chen B, Tan P, Kurpiewski S, Cai Z. Poly (ADP-ribose) polymerases as PET imaging targets for central nervous system diseases. Frontiers In Medicine 2022, 9: 1062432. PMID: 36438061, PMCID: PMC9685622, DOI: 10.3389/fmed.2022.1062432.
• P-304 The synthesis and bioevaluation of a novel and brain penetrable PARP1 tracer [18F]Pamiparib in rodents and nonhuman primatesTong J, Chen B, Gu J, Alluri S, Zheng M, Zheng C, Felchner Z, Gao H, Zhang L, Kapinos M, Labaree D, Ropchan J, Nabulsi N, Carson R, Huang Y, Cai Z. P-304 The synthesis and bioevaluation of a novel and brain penetrable PARP1 tracer [18F]Pamiparib in rodents and nonhuman primates. Nuclear Medicine And Biology 2022, 108: s214-s215. DOI: 10.1016/s0969-8051(22)00440-1.
• P-303 Synthesis and preclinical evaluation of PD-L1 PET tracer [18F]FDHPA in miceTong J, Chen B, Alluri S, Gu J, Zheng M, Zheng C, Felchner Z, Gao H, Zhang L, Kapinos M, Labaree D, Ropchan J, Nabulsi N, Marquez-Nostra B, Carson R, Huang Y, Cai Z. P-303 Synthesis and preclinical evaluation of PD-L1 PET tracer [18F]FDHPA in mice. Nuclear Medicine And Biology 2022, 108: s214. DOI: 10.1016/s0969-8051(22)00439-5.
• P-278 Development and preliminary evaluation of the fluorine-18 labeled benzamido-dihydroindene derivative [18F]FBAIN as a potential radiotracer for PET imaging of the chemokine receptor CXCR5Lindemann M, Tong J, Chen B, Kranz M, Oteiza A, Martin-Armas M, Sadasivam P, Drake L, Liu M, Spencer E, Huang Y, Cai Z. P-278 Development and preliminary evaluation of the fluorine-18 labeled benzamido-dihydroindene derivative [18F]FBAIN as a potential radiotracer for PET imaging of the chemokine receptor CXCR5. Nuclear Medicine And Biology 2022, 108: s200-s201. DOI: 10.1016/s0969-8051(22)00414-0.
• PET Imaging of Synaptic Vesicle Protein 2AFinnema S, Li S, Cai Z, Naganawa M, Chen M, Matuskey D, Nabulsi N, Esterlis I, Holmes S, Radhakrishnan R, Toyonaga T, Huang Y, Carson R. PET Imaging of Synaptic Vesicle Protein 2A. 2020, 993-1019. DOI: 10.1007/978-3-030-53176-8_29.
• Synthesis and Preclinical Evaluation of an 18F‑Labeled Synaptic Vesicle Glycoprotein 2A PET Imaging Probe: [18F]SynVesT‑2Cai Z, Li S, Zhang W, Pracitto R, Wu X, Baum E, Finnema SJ, Holden D, Toyonaga T, Lin SF, Lindemann M, Shirali A, Labaree DC, Ropchan J, Nabulsi N, Carson RE, Huang Y. Synthesis and Preclinical Evaluation of an 18F‑Labeled Synaptic Vesicle Glycoprotein 2A PET Imaging Probe: [18F]SynVesT‑2. ACS Chemical Neuroscience 2020, 11: 592-603. PMID: 31961649, DOI: 10.1021/acschemneuro.9b00618.
• PET imaging of synaptic density: A new tool for investigation of neuropsychiatric diseasesCai Z, Li S, Matuskey D, Nabulsi N, Huang Y. PET imaging of synaptic density: A new tool for investigation of neuropsychiatric diseases. Neuroscience Letters 2018, 691: 44-50. PMID: 30075287, PMCID: PMC6339829, DOI: 10.1016/j.neulet.2018.07.038.
• PET Imaging for Early Detection of Alzheimer’s Disease From Pathologic to Physiologic BiomarkersBao W, Jia H, Finnema S, Cai Z, Carson RE, Huang YH. PET Imaging for Early Detection of Alzheimer’s Disease From Pathologic to Physiologic Biomarkers. PET Clinics 2017, 12: 329-350. PMID: 28576171, DOI: 10.1016/j.cpet.2017.03.001.